dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Udaondo, Patricia |
dc.contributor.author | Hernández Pascual, Cristina |
dc.contributor.author | Brianso Llort, Laura |
dc.contributor.author | García-Delpech, Salvador |
dc.contributor.author | Simó Servat, Olga |
dc.contributor.author | Simó Canonge, Rafael |
dc.date.accessioned | 2020-09-07T11:18:21Z |
dc.date.available | 2020-09-07T11:18:21Z |
dc.date.issued | 2019-11-02 |
dc.identifier.citation | Udaondo P, Hernández C, Briansó-Llort L, García-Delpech S, Simó-Servat O, Simó R. Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study. J Clin Med. 2019 Nov 2;8(11):1841. |
dc.identifier.issn | 2077-0383 |
dc.identifier.uri | https://hdl.handle.net/11351/5221 |
dc.description | Diabetic macular edema; Anti-VEGF agents; Aqueous humor |
dc.description.abstract | The objective was to investigate the usefulness of the “liquid biopsy” of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11), and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines, chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders. In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers than rapid responders, but did not reach statistical significance. Finally, those patients who responded to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than patients with rapid response (p = 0.01). In conclusion, “liquid biopsy” of AH could be useful to determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in nature. This approach would allow physicians to select a more rational and cost-effective treatment. Further studies to validate these preliminary results are warranted. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Clinical Medicine;8(11) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Biòpsia |
dc.subject | Factors de creixement fibroblàstic |
dc.subject | Retinopatia diabètica |
dc.subject.mesh | Liquid Biopsy |
dc.subject.mesh | Macular Edema |
dc.subject.mesh | Vascular Endothelial Growth Factors |
dc.subject.mesh | /antagonists & inhibitors |
dc.title | Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jcm8111841 |
dc.subject.decs | biopsia líquida |
dc.subject.decs | edema macular |
dc.subject.decs | factores de crecimiento endotelial vascular |
dc.subject.decs | /antagonistas & inhibidores |
dc.relation.publishversion | https://www.mdpi.com/2077-0383/8/11/1841 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Udaondo P, García-Delpech S] Department of Ophthalmology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [Hernández C, Briansó-Llort L, Simó-Servat O, Simó R] Grup de Recerca en Diabetis i metabolisme, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain |
dc.identifier.pmid | 31684007 |
dc.identifier.wos | 000502294400084 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00541 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |